Moderna, Inc. (MRNA): Form 8-K filed 2026-11-13
- Accepted by EDGAR
- 2026-11-13 16:01 ET
- Event date
- 2026-11-13
- Accession no.
- 0001682852-26-000205
- Original filing
- SEC EDGAR filing index
AI summary of the filing text. It can contain mistakes; the original filing is authoritative.
Moderna discloses Chief Legal Officer Shannon Thyme Klinger's retirement agreement
Moderna entered into a retirement agreement with Chief Legal Officer Shannon Thyme Klinger on November 13, 2026, providing for continued employment until March 31, 2027. The agreement includes severance, COBRA premium payments and conditional payments tied to litigation outcomes.
- Shannon Thyme Klinger will continue employment until March 31, 2027 and transition her duties as requested.
- Severance totals $1,628,300, paid in substantially equal biweekly installments over the twelve months after retirement.
- Moderna will pay COBRA premiums until September 30, 2028, subject to earlier termination conditions.
- Klinger is eligible for $2,500,000 and up to $5,500,000 in additional payments tied to specified litigation outcomes.
executive change
Items reported
- Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
A director or a named officer (such as the CEO or CFO) left or was appointed, or certain executive compensation arrangements were adopted or changed. - Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | 8-K | mrna-20261113.htm |
| EX-10.1 | EX-10.1 | exhibit101-111326.htm |
The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.